Neuroprotection by tetracyclines

被引：170

作者：

Domercq, M ^{[1
]}

Matute, C ^{[1
]}

机构：

[1] Univ Basque Country, Dept Neurociencias, E-48940 Leioa, Vizcaya, Spain

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2004年 / 25卷 / 12期

关键词：

D O I：

10.1016/j.tips.2004.10.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The neuroprotective properties of tetracyclines have been clearly established in rodent models of acute and chronic neurodegeneration during the past few years. Recent findings have provided novel insights into the molecular and cellular mechanisms of protection of neurons and oligodendrocytes by tetracyclines. These advances have prompted several clinical trials with minocycline, the most effective tetracycline, which are still in their early phases. Thus, tetracyclines hold great promise as therapeutic agents for the treatment of human neurodegenerative diseases.

引用

收藏

页码：609 / 612

页数：4

相关论文

共 30 条

[1] Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury [J].

Arvin, KL ;

Han, BH ;

Du, YS ;

Lin, SZ ;

Paul, SM ;

Holtzman, DM .

ANNALS OF NEUROLOGY, 2002, 52 (01) :54-61

[2] Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion [J].

Barnett, MH ;

Prineas, JW .

ANNALS OF NEUROLOGY, 2004, 55 (04) :458-468

[3] Targeting leukocyte MMPs and transmigration - Minocycline as a potential therapy for multiple sclerosis [J].

Brundula, V ;

Rewcastle, NB ;

Metz, LM ;

Bernard, CC ;

Yong, VW .

BRAIN, 2002, 125 :1297-1308

[4]

Cha JH, 2004, NEUROLOGY, V63, P547

[5] Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease [J].

Chen, M ;

Ona, VO ;

Li, MW ;

Ferrante, RJ ;

Fink, KB ;

Zhu, S ;

Bian, J ;

Guo, L ;

Farrell, LA ;

Hersch, SM ;

Hobbs, W ;

Vonsattel, JP ;

Cha, JHJ ;

Friedlander, RM .

NATURE MEDICINE, 2000, 6 (07) :797-+

[6] REDUCTION OF CENTRAL-NERVOUS-SYSTEM REPERFUSION INJURY IN RABBITS USING DOXYCYCLINE TREATMENT [J].

CLARK, WM ;

CALCAGNO, FA ;

GABLER, WL ;

SMITH, JR ;

COULL, BM .

STROKE, 1994, 25 (07) :1411-1415

[7] Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease [J].

Diguet, E ;

Fernagut, PO ;

Wei, X ;

Du, YS ;

Rouland, R ;

Gross, C ;

Bezard, E ;

Tison, F .

EUROPEAN JOURNAL OF NEUROSCIENCE, 2004, 19 (12) :3266-3276

[8] Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease [J].

Du, YS ;

Ma, ZZ ;

Lin, SZ ;

Dodel, RC ;

Gao, F ;

Bales, KR ;

Triarhou, LC ;

Chernet, E ;

Perry, KW ;

Nelson, DLG ;

Luecke, S ;

Phebus, LA ;

Bymaster, FP ;

Paul, SM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (25) :14669-14674

[9] Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection [J].

Fagan, SC ;

Edwards, DJ ;

Borlongan, CV ;

Xu, L ;

Arora, A ;

Feuerstein, G ;

Hess, DC .

EXPERIMENTAL NEUROLOGY, 2004, 186 (02) :248-251

[10] Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis [J].

Gordon, PH ;

Moore, DH ;

Gelinas, DF ;

Qualls, C ;

Meister, ME ;

Werner, J ;

Mendoza, M ;

Mass, J ;

Kushner, G ;

Miller, RG .

NEUROLOGY, 2004, 62 (10) :1845-1847